Mainz Biomed B.V. (MYNZ) 6-K 15 Aug 23 Management’s Discussion and Analysis of Financial Condition and Results of Operations Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2023
Document Information Line Items
Entity Registrant Name	MAINZ BIOMED N.V.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001874252
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity File Number	001-41010

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 10,911,087	$ 17,141,775
Trade and other receivables, net	370,931	259,138
Inventories	387,178	175,469
Prepaid expenses	455,934	801,959
Total current assets	12,125,130	18,378,341
Property and equipment, net	1,617,228	661,692
Intangible assets	3,630,384
Right-of-use assets	1,932,258	1,177,695
Other assets	106	23,275
Total assets	19,305,106	20,241,003
Current Liabilities
Accounts payable and accrued liabilities	4,326,662	2,916,679
Convertible loan	43,637	43,057
Convertible promissory note at fair value	5,015,000
Convertible debt - related party	32,615	32,181
Silent partnership	211,994	759,168
Silent partnership - related party	211,994	206,167
Payable for acquisition of intangible asset current portion – related party	393,483
Lease liabilities	472,767	285,354
Total current liabilities	10,708,152	4,242,606
Silent partnerships	721,137	687,128
Silent partnerships - related party	263,324	256,086
Lease liabilities	1,560,408	959,116
Intellectual property acquisition liability - related party	874,698
Total liabilities	14,127,719	6,144,936
Shareholders’ equity
Share capital	175,785	164,896
Share premium	43,212,004	38,831,542
Reserve	19,732,949	18,079,741
Accumulated deficit	(57,844,937)	(43,032,294)
Accumulated other comprehensive income (loss)	(98,414)	52,182
Total shareholders’ equity	5,177,387	14,096,067
Total liabilities and shareholders’ equity	$ 19,305,106	$ 20,241,003

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Profit and Loss and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Revenue	$ 248,945	$ 139,240	$ 499,049	$ 239,805
Cost of revenue	100,147	58,427	211,310	112,563
Gross profit	148,798	80,813	287,739	127,242
Operating expenses:
Sales and marketing	1,799,569	1,866,384	4,085,661	2,788,014
Research and development	3,478,595	229,916	5,736,373	793,488
General and administrative	2,796,724	4,932,422	4,879,351	9,125,207
Total operating expenses	8,074,888	7,028,722	14,701,385	12,706,709
Loss from operations	(7,926,090)	(6,947,909)	(14,413,646)	(12,579,467)
Other income (expense)
Other income	107,143	17,601	170,968	92,932
Other expense	(432,780)	(8,403)	(569,965)	(115,912)
Total other income (expense)	(325,637)	9,198	(398,997)	(22,980)
Loss before income tax	(8,251,727)	(6,938,711)	(14,812,643)	(12,602,447)
Income taxes provision
Net loss	(8,251,727)	(6,938,711)	(14,812,643)	(12,602,447)
Foreign currency translation gain (loss)	(90,024)	46,204	(150,596)	82,643
Comprehensive loss	$ (8,341,751)	$ (6,892,507)	$ (14,963,239)	$ (12,519,804)
Basic loss per ordinary share (in Dollars per share)	$ (0.56)	$ (0.48)	$ (1.01)	$ (0.91)
Weighted average number of ordinary shares outstanding (in Shares)	14,915,905	14,286,157	14,803,243	13,821,914

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Profit and Loss and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Dilutive loss per ordinary share	$ (0.56)	$ (0.48)	$ (1.01)	$ (0.91)

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($)	Share Capital	Share Premium	Reserve	Accumulated Deficit	Accumulated Other comprehensive Income (loss)	Total
Balance at Dec. 31, 2021	$ 141,075	$ 13,126,493	$ 9,736,066	$ (16,644,958)	$ 2,479	$ 6,361,155
Balance (in Shares) at Dec. 31, 2021	12,010,001
Sale of ordinary shares	$ 15,525	23,850,364				23,865,889
Sale of ordinary shares (in Shares)	1,725,000
Issuance of ordinary shares for exercise of warrants	$ 968	321,533	(64,156)			258,344
Issuance of ordinary shares for exercise of warrants (in Shares)	107,500
Share based expenses	$ 522	787,098				787,620
Share based expenses (in Shares)	58,000
Stock option expense			2,424,901			2,424,901
Net loss				(5,663,736)		(5,663,736)
Foreign currency translation					36,439	36,439
Balance at Mar. 31, 2022	$ 158,090	38,085,488	12,096,811	(22,308,694)	38,918	28,070,612
Balance (in Shares) at Mar. 31, 2022	13,900,501
Balance at Dec. 31, 2021	$ 141,075	13,126,493	9,736,066	(16,644,958)	2,479	6,361,155
Balance (in Shares) at Dec. 31, 2021	12,010,001
Net loss						(12,602,447)
Balance at Jun. 30, 2022	$ 163,332	38,256,659	14,514,102	(29,247,405)	85,122	23,771,810
Balance (in Shares) at Jun. 30, 2022	14,482,974
Balance at Mar. 31, 2022	$ 158,090	38,085,488	12,096,811	(22,308,694)	38,918	28,070,612
Balance (in Shares) at Mar. 31, 2022	13,900,501
Issuance of ordinary shares for exercise of warrants	$ 5,243	171,172	(52,258)			124,156
Issuance of ordinary shares for exercise of warrants (in Shares)	582,473
Share based expenses			2,469,549			2,469,549
Stock option expense
Net loss				(6,938,711)		(6,938,711)
Foreign currency translation					46,204	46,204
Balance at Jun. 30, 2022	$ 163,332	38,256,659	14,514,102	(29,247,405)	85,122	23,771,810
Balance (in Shares) at Jun. 30, 2022	14,482,974
Balance at Dec. 31, 2022	$ 164,896	38,831,542	18,079,741	(43,032,294)	52,182	14,096,067
Balance (in Shares) at Dec. 31, 2022	14,629,457
Sale of ordinary shares	$ 2,094	1,281,291				1,283,385
Sale of ordinary shares (in Shares)	195,044
Share based expenses	$ 22	14,741				14,763
Share based expenses (in Shares)	2,112
Stock option expense			904,664			904,664
Net loss				(6,560,916)		(6,560,916)
Foreign currency translation					(60,572)	(60,572)
Balance at Mar. 31, 2023	$ 167,012	40,127,574	18,984,405	(49,593,210)	(8,390)	9,677,391
Balance (in Shares) at Mar. 31, 2023	14,826,613
Balance at Dec. 31, 2022	$ 164,896	38,831,542	18,079,741	(43,032,294)	52,182	14,096,067
Balance (in Shares) at Dec. 31, 2022	14,629,457
Net loss						(14,812,643)
Balance at Jun. 30, 2023	$ 175,785	43,212,004	19,732,949	(57,844,937)	(98,414)	5,177,387
Balance (in Shares) at Jun. 30, 2023	15,631,521
Balance at Mar. 31, 2023	$ 167,012	40,127,574	18,984,405	(49,593,210)	(8,390)	9,677,391
Balance (in Shares) at Mar. 31, 2023	14,826,613
Sale of ordinary shares	$ 1,224	608,587				609,811
Sale of ordinary shares (in Shares)	112,321
Ordinary shares issued for acquisition of intangible asset	$ 3,270	2,051,730				2,055,000
Ordinary shares issued for acquisition of intangible asset (in Shares)	300,000
Ordinary shares issued for commission of issuance of convertible debt	$ 593	249,407				250,000
Ordinary shares issued for commission of issuance of convertible debt (in Shares)	54,428
Ordinary shares issued for cashless exercise of warrants	$ 3,333	12,132	(15,465)
Ordinary shares issued for cashless exercise of warrants (in Shares)	305,771
Share based expenses	$ 353	162,574				162,927
Share based expenses (in Shares)	32,388
Stock option expense			764,009			764,009
Net loss				(8,251,727)		(8,251,727)
Foreign currency translation					(90,024)	(90,024)
Balance at Jun. 30, 2023	$ 175,785	$ 43,212,004	$ 19,732,949	$ (57,844,937)	$ (98,414)	$ 5,177,387
Balance (in Shares) at Jun. 30, 2023	15,631,521

Condensed Interim Consolidate_5

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows From Operating Activities
Net loss	$ (14,812,643)	$ (12,602,447)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share based compensation	2,096,363	5,682,070
Depreciation and amortization	458,368	62,369
Bad debt expense	53,295	470
Accretion expense	88,759	40,697
Change in fair value of convertible debt	(45,000)
Changes in operating assets and liabilities:
Trade and other receivables	58,898	(47,371)
Inventory	(208,367)	(38,269)
Prepaid expenses and other assets	372,018	332,078
Accounts payable and accrued liabilities	1,161,515	113,499
Deferred revenue	(1,331)
Net cash used in operating activities	(10,778,125)	(6,456,904)
Cash Flows From Investing Activities
Purchase of intangible asset	(500,000)
Purchase of property and equipment	(1,024,555)	(252,446)
Net cash used in investing activities	(1,524,555)	(252,446)
Cash Flows From Financing Activities
Sale of ordinary shares	1,894,742	23,865,890
Warrant exercise proceeds		382,500
Proceeds from issuance of convertible debt	5,060,000
Repayment of loans payable	(560,755)	(111,049)
Payment of lease obligations	(201,480)	(45,690)
Net cash provided by financing activities	6,192,507	24,091,651
Effect of changes in exchange rates	(120,515)	(103,234)
Net change in cash	(6,230,688)	17,279,067
Cash at beginning of period	17,141,775	8,727,542
Cash at end of period	10,911,087	26,006,609
Non-Cash Investing And Financing Activities
Right of use asset additions	969,813
Acquisition of intangible asset for payable and stock payable	3,271,828
Interest expense paid	$ 104,822

Nature of Operations and Going

Nature of Operations and Going Concern	6 Months Ended
	Jun. 30, 2023
Nature of Operations and Going Concern [Abstract]
NATURE OF OPERATIONS AND GOING CONCERN	NOTE 1. NATURE OF OPERATIONS AND GOING CONCERN Mainz Biomed N.V. (the “Company”) is domiciled in the Netherlands. The Company’s registered office is at Keizersgracht 391A, EJ Amsterdam and its headquarters are in Mainz, Germany. The Company was formed to acquire the business of Mainz Biomed Germany GmbH (f/k/a PharmGenomics GmbH (“PharmaGenomics”, “PG”)). In September 2021, the Company completed such acquisition. We develop in-vitro diagnostic (“IVD”) tests for clinical diagnostics in the area of human genetics, focusing in the areas of personalized medicine, led by our flagship ColoAlert™ product in European markets. We additionally operate a clinical diagnostic laboratory. We develop and distribute our IVD kits to third-party laboratories and through our on-line store. Throughout these consolidated financial statements, Mainz Biomed N.V. and its wholly owned subsidiaries, Mainz Biomed USA, Inc. and Mainz Biomed GmbH (f/k/a PharmGenomics GmbH), are referred to, collectively and individually as “Mainz”, “Mainz Biomed”, or the “Company”. Share Exchange On August 3, 2021, the Company entered into a contribution agreement (the “Contribution Agreement”) between Mainz Biomed B.V. (“Mainz”), which was a private company with limited liability under Dutch law incorporated for the purpose of acquiring PharmGenomics. Under the Contribution Agreement, 100% of the shares of PharmGenomics were acquired in exchange for 6,000,000 shares of the Company. Upon the closing of the Contribution Agreement, PharmGenomics became a wholly owned subsidiary of the Company and the former shareholders of PharmGenomics held approximately 62% of the outstanding shares of the Company prior to the Company’s initial public offering. On September 20, 2021, PharmGenomics and the Company closed the Contribution Agreement. IPO and Follow-on Equity Offering In November 2021, the Company completed its initial public offering (“IPO”) of its ordinary shares on the Nasdaq Capital Market, selling 2,300,000 shares at $5.00 per share. Upon its IPO, Mainz Biomed B.V. became Mainz Biomed N.V. In January 2022, the Company completed a follow on offering of its ordinary shares, selling 1,725,000 ordinary shares for gross proceeds of approximately $25.9 million (proceeds net of offering expenses was $23.9 million). Going Concern The Company has recurring losses, accumulated deficit totaling $57,844,937 and negative cash flows used in operating activities of $10,778,125 as of and for the six months ended June 30, 2023. The Company also had $10,911,087 of cash on hand on June 30, 2023 and working capital, excluding liabilities expected to be settled with ordinary shares, of $6,431,978. These conditions are indicators that impact the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. If the Company is unable to obtain funding, the Company could be forced to further delay, reduce or eliminate its research and development, regulatory, and commercial efforts which could adversely affect its future business prospects and its ability to continue as a going concern. The Company plans to fund its cash flow and working capital needs through current cash on hand and future debt and/or equity financings which it may obtain through one or more public or private equity offerings, debt financings, government or other third-party funding, strategic alliances or collaboration agreements. In December 2022, the Company entered into a $50,000,000 Controlled Equity Offering (see Note 13); the Company raised $1.9 million of net cash from this facility during the six months ended June 30, 2023. Additionally, on June 28, 2023, the Company entered into a Pre Paid Advance Agreement and issued a $5.5 million convertible promissory note (see Note 11) for net proceeds of $5.1 million. Management believes that the availability of its Controlled Equity Offering and/or Pre Paid Advance Agreement, combined with the potential to execute a financing after the reporting of results from its clinical studies, will provide the financing necessary to fund the Company’s working capital needs for the foreseeable future. These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These financial statements do not reflect the adjustments to the carrying values of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used, that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. COVID-19 Impact On March 11, 2020, the outbreak of the novel strain of coronavirus specifically identified as “COVID-19” was declared a pandemic by the World Health Organization. The outbreak has resulted in governments worldwide enacting emergency measures to combat the spread of the virus which in turn have caused material disruption to business globally. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions and the severity and frequency of new strains of the coronavirus. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company in future periods.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Disclosure of Basis of Presentation [Abstract]
BASIS OF PRESENTATION	NOTE 2. BASIS OF PRESENTATION Basis of Presentation and Statement of Compliance These condensed interim financial statements have been prepared in accordance with International Accounting Standards (“IAS”) 34, “Interim Financial Reporting” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and International Financial Reporting Interpretations Committee (“IFRIC”). These condensed interim financial statements do not include all of the information required of a full set of annual financial statements and are intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that these condensed interim financial statements be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2022 and notes thereto contained in the Company’s Form 20-F. These condensed interim financial statements have been prepared on a historical cost basis, modified where applicable. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting except for cash flow information. The condensed unaudited interim financial statements were authorized for issuance by the Audit Committee of the Board of Directors on August 11, 2023.

Accounting Policies, Estimates

Accounting Policies, Estimates and Significant Management Judgments	6 Months Ended
	Jun. 30, 2023
Significant accounting policies [Abstract]
ACCOUNTING POLICIES, ESTIMATES AND SIGNIFICANT MANAGEMENT JUDGMENTS	NOTE 3. ACCOUNTING POLICIES, ESTIMATES AND SIGNIFICANT MANAGEMENT JUDGMENTS Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on a weighted average cost and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. Critical Accounting Estimates and Significant Management Judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Useful lives of property and equipment Estimates of the useful lives of property and equipment are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment would increase the recorded expenses and decrease the non-current assets. Provision for expected credit losses on trade receivables The provision for expected credit losses on trade receivables are estimated based on historical information, customer concentrations, customer solvency, current economic and geographical trends, and changes in customer payment terms and practices. The Company will calibrate its provision matrix to adjust the historical credit loss experience with forward-looking information. The assessment of the correlation between historical observed default rates, forecast economic conditions and expected credit losses is a significant estimate. The amount of expected credit losses is sensitive to changes in circumstances and of forecast economic conditions. The Company’s historical credit loss experience and forecast of economic conditions may also not be representative of customer’s actual default in the future. Estimating the incremental borrowing rate on leases The Company cannot readily determine the interest rate implicit in leases where it is the lessee. As such, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of comparable value to the right-of-use asset in a similar economic environment. IBR therefore reflects what the Company “would have to pay”, which requires estimation when no observable rates are available or where the applicable rates need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates. Estimating the fair value of share-based payment transactions The Company utilizes a Black-Scholes model, or where appropriate, a Monte-Carlo Simulation to estimate the fair value of its share-based payments. In applying these models, management must estimate the expected future volatility of the Company’s estimated share price and makes such assumptions based on a proxy of publicly-listed entities under an expectation that historical volatility is representative of the expected future volatility. Additionally, estimates have been made by management, in respect of the performance warrants, regarding the length of the vesting period as well as the number of performance warrants that are likely to vest. Estimating the fair value of financial instruments When the Company recognizes a financial instrument, where there is no active market for such instrument, the Company utilizes alternative valuation methods. The Company utilizes inputs from observable markets to the extent that an appropriate market can be identified, but when there is a lack of such a market, the Company applies judgment to determine a fair value. Such judgments require those such as risk and volatility, of which changes in such assumptions may impact the fair value of the financial instrument. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include: ● The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty; ● The determination of the lease term of contracts with renewal and termination options; ● Determination of the extent to which it is probable that future taxable income will be available to allow all or part of the temporary differences and net operating losses to be utilized; ● Whether there are indicators of impairment of the Company’s long-lived assets; ● Development costs do not meet the conditions for capitalization in accordance with IAS 38 and therefore all research and development costs have been expensed as incurred.

Trade and Other Receivables

Trade and Other Receivables	6 Months Ended
	Jun. 30, 2023
Trade and other receivables [Abstract]
TRADE AND OTHER RECEIVABLES	NOTE 4. TRADE AND OTHER RECEIVABLES June 30, December 31, 2023 2022 Accounts receivable $ 145,681 $ 130,588 Less: allowance for doubtful accounts (50,241 ) (66,852 ) Accounts receivable, net 95,440 63,736 VAT receivable, net 275,491 192,154 Other - 3,248 $ 370,931 $ 259,138 For the six months ended June 30, 2023, the Company recorded bad debt reserve of $53,295 for VAT receivable.

Prepaid and Other Current Asset

Prepaid and Other Current Assets	6 Months Ended
	Jun. 30, 2023
Prepaid and Other Current Assets [Abstract]
PREPAID AND OTHER CURRENT ASSETS	NOTE 5. PREPAID AND OTHER CURRENT ASSETS June 30, December 31, 2023 2022 Prepaid insurance $ 213,045 $ 624,033 Other prepaid expense 109,879 55,356 Security deposit 133,010 122,570 $ 455,934 $ 801,959

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6. PROPERTY AND EQUIPMENT Laboratory Office Construction Total Cost Balance at December 31, 2022 $ 579,261 $ 176,347 $ - $ 755,608 Additions 837,200 172,594 45,338 1,055,132 Disposal - - - - Effects of currency translation 11,736 3,186 212 15,134 Balance at June 30, 2023 $ 1,428,197 $ 352,127 $ 45,550 $ 1,825,874 Accumulated depreciation Balance at December 31, 2022 $ 75,650 $ 18,266 $ - $ 93,916 Depreciation 53,681 59,252 - 112,933 Disposal - - - - Effects of currency translation 1,228 569 - 1,797 Balance at June 30, 2023 $ 130,559 $ 78,087 $ - $ 208,646 Net book value at June 30, 2022 $ 503,611 $ 158,081 $ - $ 661,692 Net book value at June 30, 2023 $ 1,297,638 $ 274,040 $ 45,550 $ 1,617,228

Intangible asset

Intangible asset	6 Months Ended
	Jun. 30, 2023
Intangible assets [Abstract]
INTANGIBLE ASSET	NOTE 7. INTANGIBLE ASSET Our flagship product is ColoAlert, a colorectal cancer (“CRC”) screening test. On January 1, 2019, we entered into an exclusive licensing agreement (the “Licensing Agreement”) with ColoAlert AS to license the intellectual property related to the ColoAlert test. On February 11, 2021, we obtained an option exercisable for three years to acquire the intellectual property for the ColoAlert test for (i) either a one-time cash payment of €2,000,000 or a €4,000,000 payment in ordinary shares at the valuation of our most recent financing plus (ii) a lifetime royalty payment of €5 per ColoAlert test sold (the “Option”). Subsequent to February 11, 2021, ColoAlert AS assigned their interest in ColoAlert and in the Licensing Agreement and the Option to Uni Targeting Research AS. On February 15, 2023, we entered into an Intellectual Property Asset Purchase Agreement (“IPA”), which supersedes the Licensing and Options Agreements. Pursuant to the IPA, we acquired the intellectual property underlying the ColoAlert test. Pursuant to the IPA, we were able to reduce the price paid for the intellectual property to (i) $2 million cash, to be paid out over the next four years, (ii) 300,000 ordinary restricted shares and (iii) a revenue share limited to $1 per test sold for a period of 10 years. The Company recognized an intangible asset from this purchase and assigned a 10-year useful life. The intangible assets were valued: (a) for the portion to be settled in stock of the Company at the value on the day of closing, or $6.85 per share, and (b) for the cash portion, at the present value of the future payments using a 10% discount. During the six months ended June 30, 2023 the Company paid $500,000 to the seller. The Company recorded amortization of $141,444 and interest expense of $51,354 for the six months ended June 30, 2023.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
LEASES	NOTE 8. LEASES Right-of-Use Assets The Company leases certain assets under lease agreements. Office Laboratory Lab and Equipment Equipment Vehicle Office Space Total Cost Balance as of December 31, 2022 $ 64,226 $ 362,970 $ 94,008 $ 1,035,200 $ 1,556,404 Additions - 331,544 51,757 588,881 972,182 Effects of currency translation 865 5,634 1,383 15,268 23,150 Balance as of June 30, 2023 $ 65,091 $ 700,148 $ 147,148 $ 1,639,349 $ 2,551,736 Accumulated amortization Balance as of December 31, 2022 $ 20,707 $ 77,838 $ 22,109 $ 258,055 $ 378,709 Depreciation 6,050 93,569 26,421 109,100 235,140 Effects of currency translation 293 1,260 358 3,718 5,629 Balance as of June 30, 2023 $ 27,050 $ 172,667 $ 48,888 $ 370,873 $ 619,478 Net book value at June 30, 2022 $ 43,519 $ 285,132 $ 71,899 $ 777,145 $ 1,177,695 Net book value at June 30, 2023 $ 38,041 $ 527,481 $ 98,260 $ 1,268,476 $ 1,932,258 As of June 30, 2023, management assessed that there were no events or changes in circumstances that would require impairment testing. The carrying amount of the right-of-use assets is amortized on a straight-line basis over the life of the leases, which at June 30, 2023, had an average expected life of 5 years. Lease Liabilities The Company’s lease liabilities consist of office and laboratory equipment and office space. The present value of future lease payments was measured using an incremental borrowing rate of 10% per annum as of January 1, 2022 and January 1, 2023. Total Balance as of December 31, 2022 $ 1,244,470 Additions 972,183 Interest expenses 92,575 Lease payments (294,549 ) Effects of currency translation 18,496 Balance as of June 30, 2023 $ 2,033,175 Lease liabilities June 30, December 31, Current portion $ 472,767 $ 285,354 Long-term portion 1,560,408 959,116 Total lease liabilities $ 2,033,175 $ 1,244,470 On June 30, 2023, the Company was committed to minimum lease payments as follows: Maturity analysis June 30, Less than one year $ 317,745 One to two years 632,966 Two to three years 537,593 Three to four years 356,609 Four to five years 224,224 More than five years 501,319 Total undiscounted lease liabilities $ 2,570,456 Amount representing implicit interest (537,281 ) Lease obligations $ 2,033,175

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2023
Accounts Payable And Accrued Expenses Abstract
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, December 31, 2023 2022 Accounts payable $ 2,743,514 $ 1,333,044 Accrued liabilities 1,493,632 1,236,942 Payroll liabilities 89,516 346,693 $ 4,326,662 $ 2,916,679

Convertible Debt - Related Part

Convertible Debt - Related Party	6 Months Ended
	Jun. 30, 2023
Disclosure of Convertible Debt Related Party Explanatory [Abstract]
CONVERTIBLE DEBT - RELATED PARTY	NOTE 10. CONVERTIBLE DEBT – RELATED PARTY During the years ended December 31, 2019 and 2020, the Company entered into loan agreements with related parties totaling EUR417,133 (approximately $467,154) (the “2019 and 2020 Convertible Loans”). The 2019 and 2020 Convertible Loans bear interest at 3.5% and have a maturity date of September 30, 2022. While the 2019 and 2020 Convertible Loans are outstanding, the lenders are entitled to 0.5% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. As the Company incurred losses during 2021, 2020 and 2019, no expense has been recorded in any period for profit sharing. At maturity, the 2019 and 2020 Convertible Loans are convertible into ordinary shares of the Company at EUR1 per share. The 2019 and 2020 Convertible Loans were determined to be a financial instrument comprising an equity classified conversion feature with a host debt component. On initial recognition, the Company used the residual value method to allocate the principal amount of the 2019 and 2020 Convertible Loans between the two components. The host debt component was valued first, based on similar debt securities without an embedded conversion feature and the residual was allocated to the equity-classified conversion feature. The Company recognized debt discounts totaling EUR13,064 on issuance of the 2019 and 2020 Convertible Loans. As of June 30, 2023 and December 31, 2022, the Company’s Convertible Debt – Related Party is $32,615 (EUR30,000) and $32,181 (EUR30,000), respectively.

Convertible Debt

Convertible Debt	6 Months Ended
	Jun. 30, 2023
Disclosure of Convertible Debt Explanatory [Abstract]
CONVERTIBLE DEBT	NOTE 11. CONVERTIBLE DEBT Convertible Loans In November 2017, the Company entered into loan agreements with two shareholders of the Company for loans totaling EUR80,278 (approximately $92,007) (the “2017 Convertible Loans”). The loans are convertible at the option of the lender to shares totaling 4.25% of the Company’s common shares outstanding at the time of conversion. The loans are non-interest bearing, are unsecured and are due on demand. During the year ended December 31, 2019, principal in the amount of EUR5,000 ($5,597) was exchanged for the 2019 and 2020 Convertible Loans and EUR5,000 ($5,597) was extinguished as the lender elected to offset the debt amount against amounts in trade receivables due to the Company. Convertible Promissory Note On June 28, 2023, we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd. (“Holder”). Pursuant to the PPA, we may request that the Holder purchase from us up to $50,000,000 (the “Commitment Amount”) of promissory notes (each, a “Promissory Note”). The Holder will purchase each Promissory Note at 92% of the principal amount of that Promissory Note. On June 28, 2023, we sold the Holder a Promissory Note (the “Initial Promissory Note”) in the principal amount of $5,500,000. The Holder is not obligated to purchase any additional Promissory Notes from us under the PPA. Each Promissory Notes matures one year from the date of its issuance. The Promissory Notes do not carry any interest, except if there is an event of default in which case the interest will increase to 15% per annum. We may prepay a Promissory Note with at an 8% premium with advance written notice ranging between five business days and thirty calendar days prior to such prepayment, depending on the market price of our ordinary shares at the time of the notice. The Promissory Notes are convertible at the Holder’s discretion into our ordinary shares at a conversion price (the “Conversion Price”) equal to the lower of (a) (I) $4.9986 in respect of the Initial Promissory Note and (II) with respect to each subsequent Promissory Note, if any, 110% of the volume weighted average price (“VWAP”) of our ordinary shares on the trading day immediately preceding the issuance of such Promissory Note (the “Fixed Price”) or (b) 92% of the average of the two lowest daily VWAPs of the shares during the eight trading days immediately prior to such conversion. In no event, however, shall the conversion price be less than a floor price of $2.00, as may be adjusted for stock splits and other similar transactions (the “Floor Price”). Under the Promissory Notes, a “Trigger Event” occurs if the trading price of an ordinary share is lower than the applicable Floor Price for any five of seven consecutive trading days. Within five trading days of a Trigger Event, we must make a monthly cash payment to the Holder in connection with the Promissory Notes (the “Monthly Payment”) equal to the lesser of (i) $550,000, plus an 8% redemption premium on any principal being repaid plus any accrued and unpaid interest and (ii) all principal outstanding under all outstanding Promissory Notes, plus an 8% redemption premium on any principal being repaid plus any accrued and unpaid interest. Thereafter, we must pay the Holder a Monthly Payment every 30 calendar days after the due date of the initial Monthly Payment; provided that our monthly obligation hereunder will end with respect to a particular Trigger Event if (i) the daily VWAP of the ordinary shares for seven consecutive trading days immediately prior to the due date of the next Monthly Payment is 10% or greater than the Floor Price or (ii) we reduce the Floor Price for all outstanding Promissory Notes by 50%, unless a new Trigger Event occurs. In connection with the execution of the PPA, we agreed to pay a commitment fee of $250,000. Such commitment fee was paid on the date of the PPA in the form of 54,428 ordinary shares, which was derived using a per ordinary share price equal to the average of the daily VWAPs of the Ordinary Shares during the three trading days prior to the PPA. The Company elected to account for the Promissory Note at fair value as of the June 28, 2023 issuance date. Management believes that the fair value option appropriately reflects the underlying economics of the Promissory Notes. Under the fair value election, changes in fair value will be reported in the consolidated statements of operations, under change in fair value of debt instrument, in each reporting period subsequent to the issuance of the Promissory Note. The Initial Promissory Note has a face value of $5,500,000 and had an original issue discount of $440,000. The Company recorded the Initial Promissory Note at its fair value of $5,060,000, which was also the cash received. For the period ended June 30, 2023, the Company recorded a change in fair value of $45,000, resulting in a balance of $5,015,000 as of June 30, 2023. We classified this fair value as a Level 3 fair value measurement and used a fair value pricing model to calculate the fair value as of June 28, 2023 and June 30, 2023. Key inputs for the fair value model are summarized below. A summary of the Company’s significant inputs into the fair value of the Initial Promissory Note is as follows: June 28, June 30, 2023 2023 Stock price $ 4.82 $ 4.78 Expected life in years 1 1 Risk free rate 5.32 % 5.40 % Expected volatility 74.65 % 74.66 % Discount rate 79.27 % 78.54 %

Silent Partnerships

Silent Partnerships	6 Months Ended
	Jun. 30, 2023
Silent Partnerships [Abstract]
SILENT PARTNERSHIPS	NOTE 12. SILENT PARTNERSHIPS During the year ended December 31, 2020, the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR299,400 (approximately $341,740) (the “3% SPAs”). The Company is to repay the amount by December 31, 2025. The Company must pay a minimum of 3% interest per annum on the loans. The lender is entitled to 3% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. Upon the amounts coming due, the lender of the 3% SPAs has the option to demand an additional payment equal to 15% of the contribution as a final remuneration (the “Final Renumeration”). The Final Remuneration is considered to be the cost of issuing debt. The 3% SPAs were received at below market interest rates as part of a government program for COVID-19 relief. The initial fair value of the 3% SPAs was determined to be EUR218,120 (approximately $248,966), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3% SPAs of EUR81,280 ($92,774) has been recognized as government grant income during the period. During the year ended December 31, 2021 the Company received the remaining EUR200,000 ($236,640). The initial fair value of the 3.0% SPAs received was determined to be EUR230,000 (approximately $272,136), determined using an estimated effective interest rate of 11.5%. The initial fair value of the 3.0% SPAs received in 2021 was determined to be EUR156,549 (approximately $185,229), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3.0% SPAs received in 2021 of EUR43,451 (approximately $51,410) has been recognized as government grant income during the period. During the year ended December 31, 2020, the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR50,000 (approximately $57,071) (the “3.5% SPAs”). The Company is to repay the amount by June 30, 2025. The Company must pay a minimum of 3.5% interest per annum on the loans. The lender is entitled to 0.5% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. The 3.5% SPAs are convertible to common shares of the Company at EUR1 per share in the event that the Company is involved in any of the following transactions: capital increases, a share or asset deal or a public offering. Pursuant to the silent partnership agreement, the Company notified the holder, at which point the holder declined the opportunity to convert their loan into common shares. The 3.5% SPAs were determined to be a financial instrument comprising an equity classified conversion feature with a host debt component. On initial recognition, the Company used the residual value method to allocate the principal amount of the 3.5% SPAs between the two components. The host debt component was valued first, based on similar debt securities without an embedded conversion feature and the residual was allocated to the equity-classified conversion feature. Between the years of 2013 to 2016, the Company entered into silent partnership agreements for loans totaling EUR798,694 (approximately $915,383) (the “8.5% SPAs”). Under the 8.5% SPAs, the Company is to repay EUR398,634 (approximately $408,496) of the loans by June 30, 2023 (such amounts were paid between the end of June and the beginning of July 2023) and EUR400,000 (approximately $409,859) of the loans matures on December 31, 2025. The Company must pay a minimum of 8.5% interest per annum on the loans. The lenders are entitled to 1.66% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. At maturity, the lenders of the 8.5% SPAs have the option to demand an additional payment equal to 30% of the principal of the loans as a Final Remuneration. The Final Remuneration is considered to be cost of issuing the debt and as such, the initial fair value of the 8.5% SPAs was determined to be EUR772,568 (approximately $85,440), determined using an estimated effective interest rate of 11.5%. Under the agreements, the lenders also agreed to invest in the Company and contributed EUR676,366 (approximately $775,183) to acquire 27,752 shares of the Company between the years of 2013 and 2016. During the year ended December 31, 2020, EUR80,000 (approximately $99,527) of the 8.5% SPAs was extinguished as the lender, who is also a customer of the Company, elected to offset the debt amount against amounts in trade receivables due to the Company. The debtor did not demand the Final Remuneration, and the Company recognized a gain on the extinguishment of $8,214. In 2010, the Company entered into a silent partnership agreement whereby the lender agreed to lend the Company EUR300,000 (approximately $343,830) (the “8% SPA”). The Company repaid this loan in January 2023. The Company must pay a minimum of 8% interest per annum on the loan. The lender is entitled to 1.95% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. At maturity, the lender of the 8% SPA has the option to demand an additional payment of up to 30% of the principal of the loan as a Final Remuneration. The Final Remuneration is considered to be cost of issuing the debt and as such, the initial fair value of the 8% SPA was determined to be EUR289,900 (approximately $332,254), determined using an estimated effective interest rate of 11.5%. A continuity of the Company’s silent partnerships is as follows: 3% SPAs 3.5% SPAs 8.5% SPAs 8% SPAs Total Balance, December 31, 2022 $ 537,359 $ 43,938 $ 909,703 $ 417,549 $ 1,908,549 Issued during the year - - - - - Extinguished during the year - - (138,747 ) (422,008 ) (560,755 ) Discount - - - - - Accretion 20,592 1,659 14,341 812 37,404 Interest expense - - - - - Effects of currency translation 7,335 599 11,670 3,647 23,251 Balance, June 30, 2023 $ 565,286 $ 46,196 $ 796,967 $ - $ 1,408,449

Equity

Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
EQUITY	NOTE 13. EQUITY Ordinary shares The Company has 45 million ordinary shares authorized. Holders of ordinary shares are entitled to dividends as declared from time to time and are entitled to one vote per share at general meetings of the Company. The par value of share capital is EUR0.01 per share. Controlled Equity Offering In December 2022, the Company entered into a Controlled Equity Offering, known as an “ATM” facility. Pursuant to the ATM, the Company at its discretion and subject to an effective registration statement with the U.S. Securities and Exchange Commission, may sell through its agent ordinary shares at market prices, for a fee of 3%. During the six months ended June 30, 2023 the Company issued 307,365 ordinary shares pursuant to the ATM for net proceeds of $1,894,742, at an average price of $6.16. In addition, during the six months ended June 30, 2023, the Company issued ordinary shares as follows: ● 34,500 ordinary shares issued for services rendered which were valued at $177,690 ● 305,771 ordinary shares issued for cashless exercise of warrants ● 54,428 ordinary shares issued for a commitment fee on a convertible promissory note valued at $250,000 ● 300,000 ordinary shares issued for acquisition of intangible assets valued at $2,055,000 Warrants During the year ended December 31, 2021, in conjunction with private sales units, which included ordinary shares and warrants, the Company issued 3,755,000 warrants and issued 161,000 underwriter warrants with its IPO, cumulatively valued at $754,286, which was recorded to Reserve in the Statement of Financial Position. The warrants were valued using the Black-Scholes pricing model. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. Unexercised warrants expire in November 2023. During the year ended December 31, 2021, the estimated fair value of the warrants as follows: Stock price at time of issuance $ 0.283 - 1.602 Exercise price $ 3.00 Expected term 2 - 5 years Expected average volatility 75 - 95 % Expected dividend yield 0 Risk-free interest rate 0.16 - 1.08 % A summary of activity during the six months ended June 30, 2023 is as follows: Warrant Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2022 3,247,500 $ 3.00 0.44 Grants - - - Exercised (816,667 ) 3.00 - Expired - - - Balance as of June 30, 2023 2,430,833 $ 3.00 0.35 Stock options During 2021, we adopted our 2021 Omnibus Incentive Plan, and on June 28, 2022 we adopted our 2022 Omnibus Incentive Plan (the “Plans”). Under the Plans, we are authorized to issue equity incentives in the form of incentive stock options, non-statutory stock options, restricted shares, restricted share units, share appreciation rights, performance units or performance shares under separate award agreements. Under the Plans, the aggregate number of shares underlying awards that we could issue cannot exceed 3,100,000 ordinary shares. During the six months ended June 30, 2023, the Company granted 312,500 stock options valued at $1,072,612. Stock options with time-based vesting were valued using the Black-Scholes pricing model. During the six months ended June 30, 2023, the Company recorded stock based compensation of $1,668,673 and had unamortized expense of $4,519,283 as of June 30, 2023. Forfeitures are estimated at the time of grant and adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the six months ended June 30, 2023, the estimated fair values of the stock options are as follows: June 30, 2023 Exercise price $ 4.78 - 7.02 Expected term 5.25 - 7.00 years Expected average volatility 70% - 76 % Expected dividend yield - Risk-free interest rate 3.48% - 4.27 % A summary of activity during the six months ended June 30, 2023 follows: Stock options Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2022 2,394,150 $ 7.18 9.11 Grants 312,500 5.06 10.00 Exercised - - - Forfeited (27,592 ) 6.88 - Expired - - - Balance as of June 30, 2023 2,679,058 $ 6.97 8.80 Exercisable as of June 30, 2023 1,567,950 $ 5.95 8.40

Cost of Revenue

Cost of Revenue	6 Months Ended
	Jun. 30, 2023
Cost of Revenue [Abstract]
COST OF REVENUE	NOTE 14. COST OF REVENUE For the six months ended June 30, 2023 and 2022, cost of revenue consisted of test kit materials, both patient collection kits and lab based PCR kits.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 15. RELATED PARTY TRANSACTIONS Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company’s Board, its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Chief Commercial Officer and Chief Scientific Officer. The remuneration of directors and key management personnel during the six months ended June 30, 2023 and 2022 was as follows: Six months ended June 30, 2023 2022 Salaries and benefits $ 921,492 $ 1,264,187 Remuneration paid to related parties other than key personnel during the six months ended June 30, 2023 and 2022 was as follows: Six months ended June 30, 2023 2022 Salaries and benefits $ 14,956 $ 61,116 During the six months ended June 30, 2023 and 2022, the Company incurred interest expense of $16,664 and $16,838 on balances owing to related parties, respectively. During the six months ended June 30, 2023 and 2022, the Company incurred accretion expense of $6,807 and $7,885 on balances owing to related parties, respectively. During the six months ended June 30, 2023 and 2022, we recorded expenses of $52,264 and $126,173, respectively, for the cost of royalties and other associated costs owed to ColoAlert AS (and its successor, Uni Targeting Research AS, collectively “ColoAlert AS”), the company from which we exclusively licensed the ColoAlert product until we purchased the intellectual property on February 15, 2023 (see Note 7). A member of our Board of Directors is also a significant equity holder of ColoAlert AS.

Government Grants

Government Grants	6 Months Ended
	Jun. 30, 2023
Government Grants [Abstract]
GOVERNMENT GRANTS	NOTE 16. GOVERNMENT GRANTS The Company receives government grants related to its research and development activities. The amount of government grants received during the six months ended June 30, 2023 and 2022 and recognized as research grant revenue were as follows: Six months ended June 30, Research and Development Projects 2023 2022 Rapid detection of antibody-based pathogens $ - $ 19,072 Multi-marker test for the early detection of pancreatic cancer 28,117 50,037 $ 28,117 $ 69,109 As of June 30, 2023 and December 31, 2022, the grants for rapid detection of antibody-based pathogens and a multi-marker test for the early detection of pancreatic cancer had remaining grant balances of approximately $35,852 and $81,706, respectively. Grant income is included as Other Income in the condensed interim consolidated statements of profit and loss.

Financial Instrument Risk Manag

Financial Instrument Risk Management	6 Months Ended
	Jun. 30, 2023
Financial Instrument Risk Management [Abstract]
FINANCIAL INSTRUMENT RISK MANAGEMENT	NOTE 17. FINANCIAL INSTRUMENT RISK MANAGEMENT Basis of Fair Value Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are: ● Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities; ● Level 2 — Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and ● Level 3 — Inputs that are not based on observable market data. The Company’s financial instruments consist of cash, trade and other receivables, accounts payable and accrued liabilities, lease liabilities, convertible debentures, and loans payable. With the exception of convertible debentures and loans payable, the carrying value of the Company’s financial instruments approximate their fair values due to their short-term maturities. The fair value of convertible debentures and notes payable approximate their carrying value, excluding discounts, due to minimal changes in interest rates and the Company’s credit risk since issuance of the instruments. The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. Credit Risk The Company’s principal financial assets are cash and trade receivables. The Company’s credit risk is primarily concentrated in its cash which is held with institutions with a high credit worthiness. The Company carries cash balances at US financial institutions that exceed the federally insured limit of $250,000 per institution and in German financial institutions that exceed €100,000 limit per institution. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. Management believes that the Company is not exposed to any significant credit risk with respect to its cash. The Company mitigates its credit risk on receivables by actively managing and monitoring its receivables. During the six months ended June 30, 2023, the Company incurred $53,295 (related to VAT receivables) in bad debt expense (2022 - $0). The Company mitigates credit risk by evaluating the creditworthiness of customers prior to conducting business with them and monitoring its exposure for credit losses with existing customers. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company’s normal operating requirements on an ongoing basis. As of June 30, 2023, the Company had an unrestricted cash balance of $10,911,087 to settle current liabilities, excluding the Initial Promissory Note, which is expected to be settled in ordinary shares, of $6,475,516. Historically, the Company’s primary source of funding has been the issuance of ordinary shares and credit facility borrowings. The Company’s access to financing is always uncertain. There can be no assurance of continued access to equity or debt financing. The following is an analysis of the contractual maturities of the Company’s financial liabilities as of June 30, 2023: Within More than More than one year one year five years Accounts payable and accrued liabilities $ 4,326,662 $ - $ - Convertible promissory note to be settled with ordinary shares 5,015,000 - - Convertible loans 76,252 - - Silent partnerships 423,988 984,461 - Lease liabilities 472,767 1,059,089 501,319 Payable for acquisition of intangible asset - related party 393,483 874,698 - $ 10,708,152 $ 2,918,248 $ 501,319 Foreign Exchange Risk Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate its estimated short term operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which we also expect to be the currency of the Company’s largest cash outlays over the next twenty-four months. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as its financial liabilities carry interest at fixed rates. Capital Management In the management of capital, the Company includes components of stockholders’ equity. The Company aims to manage its capital resources to ensure financial strength and to maximize its financial flexibility by maintaining strong liquidity and by utilizing alternative sources of capital including equity, debt and bank loans or lines of credit to fund continued growth. The Company sets the amount of capital in proportion to risk and based on the availability of funding sources. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. As a young growth company, issuance of equity has been the primary source of capital to date. Additional debt and/or equity financing may be pursued in future as deemed appropriate to balance debt and equity. To maintain or adjust the capital structure, the Company may issue new shares, take on additional debt or sell assets to reduce debt.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2023
Concentrations [Abstract]
CONCENTRATIONS	NOTE 18. CONCENTRATIONS Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the six months ended June 30, 2023 and 2022, the Company had revenue from one and four customers that accounted for approximately 18% and 81% of revenue, respectively.

Operating Expenses

Operating Expenses	6 Months Ended
	Jun. 30, 2023
Operating Expenses [Abstract]
OPERATING EXPENSES	NOTE 19. OPERATING EXPENSES For the six months ended June 30, 2023 and 2022, operating expenses consisted of the following: Six months Ended June 30, Research and development 2023 2022 Payroll expenses $ 2,010,670 $ 539,204 Clinical study expenses 2,827,894 179,445 Depreciation and amortization 210,875 - Travel expenses 100,383 13,138 Lab consumables 35,221 97 Other expenses 551,330 61,604 $ 5,736,373 $ 793,488 Six months Ended June 30, Sales and marketing 2023 2022 Payroll $ 707,833 $ 370,597 Consulting services 1,143,077 123,333 Product and brand advertising 2,176,808 2,247,142 Other expenses 57,943 46,942 $ 4,085,661 $ 2,788,014 Six months Ended June 30, General and administrative 2023 2022 Payroll $ 923,351 $ 1,132,948 Stock option expense 1,668,673 4,894,450 Depreciation and amortization 246,710 62,369 Travel and car expenses 69,924 146,861 Consulting services 1,146,792 2,005,889 IT expense 107,101 - Training 1,050 3,755 Insurance and taxes 478,149 529,120 Rent and Premises 77,672 83,732 Other expenses 159,929 266,083 $ 4,879,351 $ 9,125,207

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20. SUBSEQUENT EVENTS Subsequent to June 30, 2023, pursuant to the PPA (see Note 11), the Holder converted $500,000 in principal value on the Initial Promissory Note, resulting in the issuance of 134,458 ordinary shares.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Inventories	Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on a weighted average cost and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation.
Critical Accounting Estimates and Significant Management Judgments	Critical Accounting Estimates and Significant Management Judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Useful lives of property and equipment Estimates of the useful lives of property and equipment are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment would increase the recorded expenses and decrease the non-current assets. Provision for expected credit losses on trade receivables The provision for expected credit losses on trade receivables are estimated based on historical information, customer concentrations, customer solvency, current economic and geographical trends, and changes in customer payment terms and practices. The Company will calibrate its provision matrix to adjust the historical credit loss experience with forward-looking information. The assessment of the correlation between historical observed default rates, forecast economic conditions and expected credit losses is a significant estimate. The amount of expected credit losses is sensitive to changes in circumstances and of forecast economic conditions. The Company’s historical credit loss experience and forecast of economic conditions may also not be representative of customer’s actual default in the future. Estimating the incremental borrowing rate on leases The Company cannot readily determine the interest rate implicit in leases where it is the lessee. As such, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of comparable value to the right-of-use asset in a similar economic environment. IBR therefore reflects what the Company “would have to pay”, which requires estimation when no observable rates are available or where the applicable rates need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates. Estimating the fair value of share-based payment transactions The Company utilizes a Black-Scholes model, or where appropriate, a Monte-Carlo Simulation to estimate the fair value of its share-based payments. In applying these models, management must estimate the expected future volatility of the Company’s estimated share price and makes such assumptions based on a proxy of publicly-listed entities under an expectation that historical volatility is representative of the expected future volatility. Additionally, estimates have been made by management, in respect of the performance warrants, regarding the length of the vesting period as well as the number of performance warrants that are likely to vest. Estimating the fair value of financial instruments When the Company recognizes a financial instrument, where there is no active market for such instrument, the Company utilizes alternative valuation methods. The Company utilizes inputs from observable markets to the extent that an appropriate market can be identified, but when there is a lack of such a market, the Company applies judgment to determine a fair value. Such judgments require those such as risk and volatility, of which changes in such assumptions may impact the fair value of the financial instrument. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include: ● The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty; ● The determination of the lease term of contracts with renewal and termination options; ● Determination of the extent to which it is probable that future taxable income will be available to allow all or part of the temporary differences and net operating losses to be utilized; ● Whether there are indicators of impairment of the Company’s long-lived assets; ● Development costs do not meet the conditions for capitalization in accordance with IAS 38 and therefore all research and development costs have been expensed as incurred.

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2023
Trade and other receivables [Abstract]
Schedule of Trade and Other Receivables	June 30, December 31, 2023 2022 Accounts receivable $ 145,681 $ 130,588 Less: allowance for doubtful accounts (50,241 ) (66,852 ) Accounts receivable, net 95,440 63,736 VAT receivable, net 275,491 192,154 Other - 3,248 $ 370,931 $ 259,138

Prepaid and Other Current Ass_2

Prepaid and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Prepaid and Other Current Assets [Abstract]
Schedule of Prepaid and Other Current Assets	June 30, December 31, 2023 2022 Prepaid insurance $ 213,045 $ 624,033 Other prepaid expense 109,879 55,356 Security deposit 133,010 122,570 $ 455,934 $ 801,959

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	Laboratory Office Construction Total Cost Balance at December 31, 2022 $ 579,261 $ 176,347 $ - $ 755,608 Additions 837,200 172,594 45,338 1,055,132 Disposal - - - - Effects of currency translation 11,736 3,186 212 15,134 Balance at June 30, 2023 $ 1,428,197 $ 352,127 $ 45,550 $ 1,825,874 Accumulated depreciation Balance at December 31, 2022 $ 75,650 $ 18,266 $ - $ 93,916 Depreciation 53,681 59,252 - 112,933 Disposal - - - - Effects of currency translation 1,228 569 - 1,797 Balance at June 30, 2023 $ 130,559 $ 78,087 $ - $ 208,646 Net book value at June 30, 2022 $ 503,611 $ 158,081 $ - $ 661,692 Net book value at June 30, 2023 $ 1,297,638 $ 274,040 $ 45,550 $ 1,617,228

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Leases Certain Assets Under Lease Agreements	The Company leases certain assets under lease agreements. Office Laboratory Lab and Equipment Equipment Vehicle Office Space Total Cost Balance as of December 31, 2022 $ 64,226 $ 362,970 $ 94,008 $ 1,035,200 $ 1,556,404 Additions - 331,544 51,757 588,881 972,182 Effects of currency translation 865 5,634 1,383 15,268 23,150 Balance as of June 30, 2023 $ 65,091 $ 700,148 $ 147,148 $ 1,639,349 $ 2,551,736 Accumulated amortization Balance as of December 31, 2022 $ 20,707 $ 77,838 $ 22,109 $ 258,055 $ 378,709 Depreciation 6,050 93,569 26,421 109,100 235,140 Effects of currency translation 293 1,260 358 3,718 5,629 Balance as of June 30, 2023 $ 27,050 $ 172,667 $ 48,888 $ 370,873 $ 619,478 Net book value at June 30, 2022 $ 43,519 $ 285,132 $ 71,899 $ 777,145 $ 1,177,695 Net book value at June 30, 2023 $ 38,041 $ 527,481 $ 98,260 $ 1,268,476 $ 1,932,258
Schedule of Future Lease Payments	The Company’s lease liabilities consist of office and laboratory equipment and office space. The present value of future lease payments was measured using an incremental borrowing rate of 10% per annum as of January 1, 2022 and January 1, 2023. Total Balance as of December 31, 2022 $ 1,244,470 Additions 972,183 Interest expenses 92,575 Lease payments (294,549 ) Effects of currency translation 18,496 Balance as of June 30, 2023 $ 2,033,175
Schedule of Lease Liabilities	Lease liabilities June 30, December 31, Current portion $ 472,767 $ 285,354 Long-term portion 1,560,408 959,116 Total lease liabilities $ 2,033,175 $ 1,244,470
Schedule of Committed to Minimum Lease Payments	On June 30, 2023, the Company was committed to minimum lease payments as follows: Maturity analysis June 30, Less than one year $ 317,745 One to two years 632,966 Two to three years 537,593 Three to four years 356,609 Four to five years 224,224 More than five years 501,319 Total undiscounted lease liabilities $ 2,570,456 Amount representing implicit interest (537,281 ) Lease obligations $ 2,033,175

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Accounts Payable And Accrued Expenses Abstract
Schedule of Accounts Payable and Accrued Expenses	June 30, December 31, 2023 2022 Accounts payable $ 2,743,514 $ 1,333,044 Accrued liabilities 1,493,632 1,236,942 Payroll liabilities 89,516 346,693 $ 4,326,662 $ 2,916,679

Convertible Debt (Tables)

Convertible Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of Convertible Debt Explanatory [Abstract]
Schedule of Convertible Debt	A summary of the Company’s significant inputs into the fair value of the Initial Promissory Note is as follows: June 28, June 30, 2023 2023 Stock price $ 4.82 $ 4.78 Expected life in years 1 1 Risk free rate 5.32 % 5.40 % Expected volatility 74.65 % 74.66 % Discount rate 79.27 % 78.54 %

Silent Partnerships (Tables)

Silent Partnerships (Tables)	6 Months Ended
	Jun. 30, 2023
Silent Partnerships [Abstract]
Schedule of Continuity of the Company’s Silent Partnerships	A continuity of the Company’s silent partnerships is as follows: 3% SPAs 3.5% SPAs 8.5% SPAs 8% SPAs Total Balance, December 31, 2022 $ 537,359 $ 43,938 $ 909,703 $ 417,549 $ 1,908,549 Issued during the year - - - - - Extinguished during the year - - (138,747 ) (422,008 ) (560,755 ) Discount - - - - - Accretion 20,592 1,659 14,341 812 37,404 Interest expense - - - - - Effects of currency translation 7,335 599 11,670 3,647 23,251 Balance, June 30, 2023 $ 565,286 $ 46,196 $ 796,967 $ - $ 1,408,449

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Estimated Fair Values of the Warrants Measured	During the year ended December 31, 2021, the estimated fair value of the warrants as follows: Stock price at time of issuance $ 0.283 - 1.602 Exercise price $ 3.00 Expected term 2 - 5 years Expected average volatility 75 - 95 % Expected dividend yield 0 Risk-free interest rate 0.16 - 1.08 % June 30, 2023 Exercise price $ 4.78 - 7.02 Expected term 5.25 - 7.00 years Expected average volatility 70% - 76 % Expected dividend yield - Risk-free interest rate 3.48% - 4.27 %
Schedule of Activity	A summary of activity during the six months ended June 30, 2023 is as follows: Warrant Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2022 3,247,500 $ 3.00 0.44 Grants - - - Exercised (816,667 ) 3.00 - Expired - - - Balance as of June 30, 2023 2,430,833 $ 3.00 0.35 Stock options Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2022 2,394,150 $ 7.18 9.11 Grants 312,500 5.06 10.00 Exercised - - - Forfeited (27,592 ) 6.88 - Expired - - - Balance as of June 30, 2023 2,679,058 $ 6.97 8.80 Exercisable as of June 30, 2023 1,567,950 $ 5.95 8.40

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Schedule of Remuneration of Directors and Key Management Personnel	The remuneration of directors and key management personnel during the six months ended June 30, 2023 and 2022 was as follows: Six months ended June 30, 2023 2022 Salaries and benefits $ 921,492 $ 1,264,187
Schedule of Remuneration Paid to Related Parties	Remuneration paid to related parties other than key personnel during the six months ended June 30, 2023 and 2022 was as follows: Six months ended June 30, 2023 2022 Salaries and benefits $ 14,956 $ 61,116

Government Grants (Tables)

Government Grants (Tables)	6 Months Ended
	Jun. 30, 2023
Government Grants [Abstract]
Schedule of Research and Development	The amount of government grants received during the six months ended June 30, 2023 and 2022 and recognized as research grant revenue were as follows: Six months ended June 30, Research and Development Projects 2023 2022 Rapid detection of antibody-based pathogens $ - $ 19,072 Multi-marker test for the early detection of pancreatic cancer 28,117 50,037 $ 28,117 $ 69,109

Financial Instrument Risk Man_2

Financial Instrument Risk Management (Tables)	6 Months Ended
	Jun. 30, 2023
Financial Instrument Risk Management [Abstract]
Schedule of Contractual Maturities Financial Liabilities	The following is an analysis of the contractual maturities of the Company’s financial liabilities as of June 30, 2023: Within More than More than one year one year five years Accounts payable and accrued liabilities $ 4,326,662 $ - $ - Convertible promissory note to be settled with ordinary shares 5,015,000 - - Convertible loans 76,252 - - Silent partnerships 423,988 984,461 - Lease liabilities 472,767 1,059,089 501,319 Payable for acquisition of intangible asset - related party 393,483 874,698 - $ 10,708,152 $ 2,918,248 $ 501,319

Operating Expenses (Tables)

Operating Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Operating Expenses [Abstract]
Schedule of Operating Expenses	For the six months ended June 30, 2023 and 2022, operating expenses consisted of the following: Six months Ended June 30, Research and development 2023 2022 Payroll expenses $ 2,010,670 $ 539,204 Clinical study expenses 2,827,894 179,445 Depreciation and amortization 210,875 - Travel expenses 100,383 13,138 Lab consumables 35,221 97 Other expenses 551,330 61,604 $ 5,736,373 $ 793,488 Six months Ended June 30, Sales and marketing 2023 2022 Payroll $ 707,833 $ 370,597 Consulting services 1,143,077 123,333 Product and brand advertising 2,176,808 2,247,142 Other expenses 57,943 46,942 $ 4,085,661 $ 2,788,014 Six months Ended June 30, General and administrative 2023 2022 Payroll $ 923,351 $ 1,132,948 Stock option expense 1,668,673 4,894,450 Depreciation and amortization 246,710 62,369 Travel and car expenses 69,924 146,861 Consulting services 1,146,792 2,005,889 IT expense 107,101 - Training 1,050 3,755 Insurance and taxes 478,149 529,120 Rent and Premises 77,672 83,732 Other expenses 159,929 266,083 $ 4,879,351 $ 9,125,207

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) - USD ($)				1 Months Ended		6 Months Ended
	Jun. 28, 2023	Jan. 31, 2022	Aug. 03, 2021	Jun. 28, 2023	Nov. 30, 2021	Jun. 30, 2023	Dec. 31, 2022
Nature of Operations and Going Concern [Abstract]
Agreement percentage			100%
Share exchange (in Shares)			6,000,000
Outstanding shares percentage			62%
Shares sold (in Shares)					2,300,000
Shares per share (in Dollars per share)					$ 5
Ordinary shares issued (in Shares)		1,725,000
Gross proceeds		$ 25,900,000
Net of offering expenses		$ 23,900,000
Accumulated deficit total						$ 57,844,937
Operating activities						10,778,125
Cash on hand						10,911,087
Ordinary shares						$ 6,431,978
Period of going concern						1 year
Equity offering							$ 50,000,000
Raised cash						$ 1,900,000
Prepaid advance agreement	$ 50,000,000			$ 5,500,000
Net proceed				$ 5,100,000

Trade and Other Receivables (De

Trade and Other Receivables (Details)	Jun. 30, 2023 USD ($)
Trade and other receivables [Abstract]
Debt reserve	$ 53,295

Trade and Other Receivables (_2

Trade and Other Receivables (Details) - Schedule of Trade and Other Receivables - USD ($)	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of trade and other receivables [Abstract]
Accounts receivable	$ 145,681	$ 130,588
Less: allowance for doubtful accounts	(50,241)	(66,852)
Accounts receivable, net	95,440	63,736
VAT receivable, net	275,491	192,154
Other		3,248
Total	$ 370,931	$ 259,138

Prepaid and Other Current Ass_3

Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Schedule of Prepaid and Other Current Assets [Abstract]
Prepaid insurance	$ 213,045	$ 624,033
Other prepaid expense	109,879	55,356
Security deposit	133,010	122,570
Total prepaid and other current assets	$ 455,934	$ 801,959

Property and Equipment (Details

Property and Equipment (Details) - Schedule of Property and Equipment	6 Months Ended
	Jun. 30, 2023 USD ($)
Cost
Cost Balance	$ 755,608
Additions	1,055,132
Disposal
Effects of currency translation	15,134
Cost Balance	1,825,874
Accumulated depreciation
Accumulated depreciation Balance	93,916
Depreciation	112,933
Disposal
Effects of currency translation	1,797
Accumulated depreciation Balance	208,646
Net book value	661,692
Accumulated depreciation net book value	1,617,228
Laboratory equipment [Member]
Cost
Cost Balance	579,261
Additions	837,200
Disposal
Effects of currency translation	11,736
Cost Balance	1,428,197
Accumulated depreciation
Accumulated depreciation Balance	75,650
Depreciation	53,681
Disposal
Effects of currency translation	1,228
Accumulated depreciation Balance	130,559
Net book value	503,611
Accumulated depreciation net book value	1,297,638
Office equipment [Member]
Cost
Cost Balance	176,347
Additions	172,594
Disposal
Effects of currency translation	3,186
Cost Balance	352,127
Accumulated depreciation
Accumulated depreciation Balance	18,266
Depreciation	59,252
Disposal
Effects of currency translation	569
Accumulated depreciation Balance	78,087
Net book value	158,081
Accumulated depreciation net book value	274,040
Construction in progress [Member]
Cost
Cost Balance
Additions	45,338
Disposal
Effects of currency translation	212
Cost Balance	45,550
Accumulated depreciation
Accumulated depreciation Balance
Depreciation
Disposal
Effects of currency translation
Accumulated depreciation Balance
Net book value
Accumulated depreciation net book value	$ 45,550

Intangible asset (Details)

Intangible asset (Details)		1 Months Ended	6 Months Ended
	Feb. 11, 2021 EUR (€) € / shares	Feb. 15, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares
Intangible asset (Details) [Line Items]
Royalty payment per share (in Euro per share) | € / shares	€ 5
intellectual property amount		$ 2,000,000
Ordinary restricted shares (in Shares) | shares		300,000
Revenue (in Dollars per share) | $ / shares		$ 1
Estimated useful life			10 years
Closing company stock (in Dollars per share) | $ / shares			$ 6.85
Future payments percentage			10%
Amount paid to seller			$ 500,000
Amortization cost			141,444
Interest expense			$ 51,354
Bottom of range [member]
Intangible asset (Details) [Line Items]
Cash Payment (in Euro) | €	€ 2,000,000
Top of range [member]
Intangible asset (Details) [Line Items]
Cash Payment (in Euro) | €	€ 4,000,000

Leases (Details)

Leases (Details)			6 Months Ended
	Jan. 01, 2023	Jan. 01, 2022	Jun. 30, 2023
Leases [Abstract]
Average expected life			5 years
Present value of future lease payments percentage	10%	10%

Leases (Details) - Schedule of

Leases (Details) - Schedule of Leases Certain Assets Under Lease Agreements	6 Months Ended
	Jun. 30, 2023 USD ($)
Cost
Balance	$ 1,556,404
Balance	2,551,736
Additions	972,182
Effects of currency translation	23,150
Accumulated amortization
Balance	378,709
Net book value	1,177,695
Accumulated depreciation net book value	1,932,258
Depreciation	235,140
Effects of currency translation	5,629
Balance	619,478
Office Equipment [Member]
Cost
Balance	64,226
Balance	65,091
Additions
Effects of currency translation	865
Accumulated amortization
Balance	20,707
Net book value	43,519
Accumulated depreciation net book value	38,041
Depreciation	6,050
Effects of currency translation	293
Balance	27,050
Laboratory Equipment [Member]
Cost
Balance	362,970
Balance	700,148
Additions	331,544
Effects of currency translation	5,634
Accumulated amortization
Balance	77,838
Net book value	285,132
Accumulated depreciation net book value	527,481
Depreciation	93,569
Effects of currency translation	1,260
Balance	172,667
Vehicle [Member]
Cost
Balance	94,008
Balance	147,148
Additions	51,757
Effects of currency translation	1,383
Accumulated amortization
Balance	22,109
Net book value	71,899
Accumulated depreciation net book value	98,260
Depreciation	26,421
Effects of currency translation	358
Balance	48,888
Lab and Office Space [Member]
Cost
Balance	1,035,200
Balance	1,639,349
Additions	588,881
Effects of currency translation	15,268
Accumulated amortization
Balance	258,055
Net book value	777,145
Accumulated depreciation net book value	1,268,476
Depreciation	109,100
Effects of currency translation	3,718
Balance	$ 370,873

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Future Lease Payments	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule of Future Lease Payments [Abstract]
Balance	$ 1,244,470
Additions	972,183
Interest expenses	92,575
Lease payments	(294,549)
Effects of currency translation	18,496
Balance	$ 2,033,175

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Lease Liabilities - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Schedule of lease liabilities [Abstract]
Current portion	$ 472,767	$ 285,354
Long-term portion	1,560,408	959,116
Total lease liabilities	$ 2,033,175	$ 1,244,470

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of Committed to Minimum Lease Payments	6 Months Ended
	Jun. 30, 2023 USD ($)
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	$ 2,570,456
Amount representing implicit interest	(537,281)
Lease obligations	2,033,175
Less than one year [Member]
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	317,745
One to two years [Member]
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	632,966
Two to three years [Member]
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	537,593
Three to four years [Member]
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	356,609
Four to five years [Member]
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	224,224
More than five years [Member]
Leases (Details) - Schedule of Committed to Minimum Lease Payments [Line Items]
Total undiscounted lease liabilities	$ 501,319

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Accounts Payable And Accrued Expenses [Abstract]
Accounts payable	$ 2,743,514	$ 1,333,044
Accrued liabilities	1,493,632	1,236,942
Payroll liabilities	89,516	346,693
Total	$ 4,326,662	$ 2,916,679

Convertible Debt - Related Pa_2

Convertible Debt - Related Party (Details)			6 Months Ended		12 Months Ended
	Nov. 30, 2017 USD ($)	Nov. 30, 2017 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 EUR (€) € / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)
Disclosure of Convertible Debt Related Party Explanatory [Abstract]
Loan agreements totaling	$ 92,007	€ 80,278					$ 467,154	€ 417,133	$ 467,154	€ 417,133
Bear interest			3.50%	3.50%
Loans outstanding, percentage			0.50%	0.50%
Convertible per share (in Euro per share) | € / shares				€ 1
Debt discount | €								€ 13,064		€ 13,064
Convertible debt related party			$ 32,615	€ 30,000	$ 32,181	€ 30,000
Convertible Debt maturity Date			Sep. 30, 2022	Sep. 30, 2022

Convertible Debt (Details)

Convertible Debt (Details)					1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 28, 2023 USD ($)	Aug. 03, 2021	Nov. 30, 2017 USD ($)	Nov. 30, 2017 EUR (€)	Jun. 28, 2023 USD ($)	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)
Convertible Debt (Details) [Line Items]
Loan agreements total			$ 92,007	€ 80,278			$ 467,154	€ 417,133	$ 467,154	€ 417,133
Convertible loan percentage			4.25%	4.25%
Convertible loan amount							$ 5,597	€ 5,000	$ 5,597	€ 5,000
Commitment amount	$ 50,000,000				$ 5,500,000
Principal amount percentage	92%				92%		3.50%	3.50%
Principal amount	$ 5,500,000
Maturity period						one
Average percentage						92%
Floor price per share (in Dollars per share) | $ / shares						$ 2
Redemption premium percentage						8%
Floor price percentage		62%
Commitment fee						$ 250,000
Ordinary shares issued for commitment fee (in Shares) | shares						54,428
Original issue discount						$ 440,000
Fair value						5,060,000
Balance of fair value						5,015,000
Conversion Price [Member]
Convertible Debt (Details) [Line Items]
Initial promissory note amount						$ 4.9986
Average percentage						110%
Initial Promissory Note [Member]
Convertible Debt (Details) [Line Items]
Face value						$ 5,500,000
Fair value						45,000
Monthly Payment [Member]
Convertible Debt (Details) [Line Items]
Redemption premium						$ 550,000
Redemption premium percentage						8%
Bottom of range [Member]
Convertible Debt (Details) [Line Items]
Promissory notes interest percentage						15%
Bottom of range [Member] | Monthly Payment [Member]
Convertible Debt (Details) [Line Items]
Floor price percentage						10%
Top of range [Member]
Convertible Debt (Details) [Line Items]
Promissory notes interest percentage						8%
Top of range [Member] | Monthly Payment [Member]
Convertible Debt (Details) [Line Items]
Floor price percentage						50%

Convertible Debt (Details) - Sc

Convertible Debt (Details) - Schedule of Convertible Debt - $ / shares	1 Months Ended	6 Months Ended
	Jun. 28, 2023	Jun. 30, 2023
Schedule Of Convertible Debt [Abstract]
Stock price (in Dollars per share)	$ 4.82	$ 4.78
Expected life in years	1 year	1 year
Risk free rate	5.32%	5.40%
Expected volatility	74.65%	74.66%
Discount rate	79.27%	78.54%

Silent Partnerships (Details)

Silent Partnerships (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€) € / shares	Dec. 31, 2010 USD ($)	Dec. 31, 2010 EUR (€)	Jun. 28, 2023
Silent Partnerships (Details) [Line Items]
Silent partnership agreements description		the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR299,400 (approximately $341,740) (the “3% SPAs”). The Company is to repay the amount by December 31, 2025. The Company must pay a minimum of 3% interest per annum on the loans. The lender is entitled to 3% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. Upon the amounts coming due, the lender of the 3% SPAs has the option to demand an additional payment equal to 15% of the contribution as a final remuneration (the “Final Renumeration”). The Final Remuneration is considered to be the cost of issuing debt. The 3% SPAs were received at below market interest rates as part of a government program for COVID-19 relief. The initial fair value of the 3% SPAs was determined to be EUR218,120 (approximately $248,966), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3% SPAs of EUR81,280 ($92,774) has been recognized as government grant income during the period. During the year ended December 31, 2021 the Company received the remaining EUR200,000 ($236,640). The initial fair value of the 3.0% SPAs received was determined to be EUR230,000 (approximately $272,136), determined using an estimated effective interest rate of 11.5%. The initial fair value of the 3.0% SPAs received in 2021 was determined to be EUR156,549 (approximately $185,229), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3.0% SPAs received in 2021 of EUR43,451 (approximately $51,410) has been recognized as government grant income during the period	the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR299,400 (approximately $341,740) (the “3% SPAs”). The Company is to repay the amount by December 31, 2025. The Company must pay a minimum of 3% interest per annum on the loans. The lender is entitled to 3% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. Upon the amounts coming due, the lender of the 3% SPAs has the option to demand an additional payment equal to 15% of the contribution as a final remuneration (the “Final Renumeration”). The Final Remuneration is considered to be the cost of issuing debt. The 3% SPAs were received at below market interest rates as part of a government program for COVID-19 relief. The initial fair value of the 3% SPAs was determined to be EUR218,120 (approximately $248,966), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3% SPAs of EUR81,280 ($92,774) has been recognized as government grant income during the period. During the year ended December 31, 2021 the Company received the remaining EUR200,000 ($236,640). The initial fair value of the 3.0% SPAs received was determined to be EUR230,000 (approximately $272,136), determined using an estimated effective interest rate of 11.5%. The initial fair value of the 3.0% SPAs received in 2021 was determined to be EUR156,549 (approximately $185,229), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3.0% SPAs received in 2021 of EUR43,451 (approximately $51,410) has been recognized as government grant income during the period
Agreed to lend a total		$ 57,071	€ 50,000	$ 343,830	€ 300,000
Convertible to common shares percentage			3.50%	8%	8%
Interest rate per annum			3.50%	8%	8%
Net income percent			0.50%
Per share (in Euro per share)			€ 1
Principal amount percentage			3.50%			92%
Net income percent				1.95%	1.95%
Additional payment percentage				30%	30%
Initial fair value rate				8%	8%
Initial fair value amount				$ 332,254	€ 289,900
SPAs [Member]
Silent Partnerships (Details) [Line Items]
Silent partnership agreements description	Between the years of 2013 to 2016, the Company entered into silent partnership agreements for loans totaling EUR798,694 (approximately $915,383) (the “8.5% SPAs”). Under the 8.5% SPAs, the Company is to repay EUR398,634 (approximately $408,496) of the loans by June 30, 2023 (such amounts were paid between the end of June and the beginning of July 2023) and EUR400,000 (approximately $409,859) of the loans matures on December 31, 2025. The Company must pay a minimum of 8.5% interest per annum on the loans. The lenders are entitled to 1.66% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. At maturity, the lenders of the 8.5% SPAs have the option to demand an additional payment equal to 30% of the principal of the loans as a Final Remuneration. The Final Remuneration is considered to be cost of issuing the debt and as such, the initial fair value of the 8.5% SPAs was determined to be EUR772,568 (approximately $85,440), determined using an estimated effective interest rate of 11.5%. Under the agreements, the lenders also agreed to invest in the Company and contributed EUR676,366 (approximately $775,183) to acquire 27,752 shares of the Company between the years of 2013 and 2016. During the year ended December 31, 2020, EUR80,000 (approximately $99,527) of the 8.5% SPAs was extinguished as the lender, who is also a customer of the Company, elected to offset the debt amount against amounts in trade receivables due to the Company. The debtor did not demand the Final Remuneration, and the Company recognized a gain on the extinguishment of $8,214.
Convertible to common shares percentage			3.50%	8%	8%
Interest rate per annum			3.50%	11.50%	11.50%

Silent Partnerships (Details) -

Silent Partnerships (Details) - Schedule of Continuity of the Company’s Silent Partnerships	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule of continuity of the company’s silent partnerships [Abstract]
Balance beginning	$ 1,908,549
Issued during the year
Extinguished during the year	(560,755)
Discount
Accretion	37,404
Interest expense
Effects of currency translation	23,251
Balance ending	1,408,449
3% SPAs [Member]
Schedule of continuity of the company’s silent partnerships [Abstract]
Balance beginning	537,359
Issued during the year
Extinguished during the year
Discount
Accretion	20,592
Interest expense
Effects of currency translation	7,335
Balance ending	565,286
3.5% SPAs [Member]
Schedule of continuity of the company’s silent partnerships [Abstract]
Balance beginning	43,938
Issued during the year
Extinguished during the year
Discount
Accretion	1,659
Interest expense
Effects of currency translation	599
Balance ending	46,196
8.5% SPAs [Member]
Schedule of continuity of the company’s silent partnerships [Abstract]
Balance beginning	909,703
Issued during the year
Extinguished during the year	(138,747)
Discount
Accretion	14,341
Interest expense
Effects of currency translation	11,670
Balance ending	796,967
8% SPAs [Member]
Schedule of continuity of the company’s silent partnerships [Abstract]
Balance beginning	417,549
Issued during the year
Extinguished during the year	(422,008)
Discount
Accretion	812
Interest expense
Effects of currency translation	3,647
Balance ending

Equity (Details)

Equity (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares € / shares shares	Dec. 31, 2021 USD ($) shares
Equity (Details) [Line Items]
Ordinary shares authorized	45,000,000	45,000,000
Vote per share	one
Share capital per share. (in Euro per share) | € / shares		€ 0.01
Ordinary shares at market prices	3%
Ordinary shares pursuant	307,365
Aggregate proceeds per share (in Dollars per share) | $ / shares	$ 1,894,742	€ 1,894,742
Net of fees and expenses (in Dollars) | $	$ 6.16
Ordinary shares issued for services	34,500	34,500
Ordinary shares value (in Dollars) | $	$ 177,690	€ 177,690
Exercise of warrants shares	305,771
Ordinary shares issued for commitment fee	54,428
Convertible promissory note value (in Dollars) | $	$ 250,000
Ordinary shares issued for acquisition	300,000
Intangible assets value (in Dollars) | $	$ 2,055,000	2,055,000
Warrants issued			3,755,000
Underwriting warrants			161,000
Underwriting warrant in amount (in Dollars) | $			$ 754,286
Granted shares	312,500
Stock options (in Dollars) | $	$ 1,072,612
Share-based compensation (in Dollars) | $	1,668,673
Unamortized expense (in Dollars) | $	$ 4,519,283	€ 4,519,283
Stock Option [Member]
Equity (Details) [Line Items]
Ordinary shares	3,100,000	3,100,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of Estimated Fair Values of the Warrants Measured - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2021
Warrants [Member]
Equity (Details) - Schedule of Estimated Fair Values of the Warrants Measured [Line Items]
Exercise price (in Dollars per share)		$ 3
Expected dividend yield (in Dollars)		$ 0
Bottom of range [Member] | Warrants [Member]
Equity (Details) - Schedule of Estimated Fair Values of the Warrants Measured [Line Items]
Stock price at time of issuance (in Dollars)		$ 0.283
Expected term		2 years
Expected average volatility		75%
Risk-free interest rate		0.16%
Bottom of range [Member] | Stock Options [Member]
Equity (Details) - Schedule of Estimated Fair Values of the Warrants Measured [Line Items]
Exercise price (in Dollars per share)	$ 4.78
Expected term	5 years 3 months
Expected average volatility	70%
Risk-free interest rate	3.48%
Top of range [Member] | Warrants [Member]
Equity (Details) - Schedule of Estimated Fair Values of the Warrants Measured [Line Items]
Stock price at time of issuance (in Dollars)		$ 1.602
Expected term		5 years
Expected average volatility		95%
Risk-free interest rate		1.08%
Top of range [Member] | Stock Options [Member]
Equity (Details) - Schedule of Estimated Fair Values of the Warrants Measured [Line Items]
Exercise price (in Dollars per share)	$ 7.02
Expected term	7 years
Expected average volatility	76%
Risk-free interest rate	4.27%

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Activity	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Warrants [Member]
Equity (Details) - Schedule of Activity [Line Items]
Outstanding, Beginning Balance | shares	3,247,500
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 3
Weighted-Average Life (years), Beginning Balance	5 months 8 days
Outstanding, Grants | shares
Weighted-Average Exercise Price, Grants | $ / shares
Weighted-Average Life (years), Grants
Outstanding, Exercised | shares	(816,667)
Weighted-Average Exercise Price, Exercised | $ / shares	$ 3
Weighted-Average Life (years), Exercised
Outstanding, Expired | shares
Weighted-Average Exercise Price, Expired | $ / shares
Weighted-Average Life (years), Expired
Outstanding, Ending Balance | shares	2,430,833
Weighted-Average Exercise Price, Ending Balance | $ / shares	$ 3
Weighted-Average Life (years), Ending Balance	4 months 6 days
Stock Option [Member]
Equity (Details) - Schedule of Activity [Line Items]
Outstanding, Beginning Balance | shares	2,394,150
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 7.18
Weighted-Average Life (years), Beginning Balance	9 years 1 month 9 days
Outstanding, Grants | shares	312,500
Weighted-Average Exercise Price, Grants | $ / shares	$ 5.06
Weighted-Average Life (years), Grants	10 years
Outstanding, Exercised | shares
Weighted-Average Exercise Price, Exercised | $ / shares
Weighted-Average Life (years), Exercised
Outstanding, Forfeited | shares	(27,592)
Weighted-Average Exercise Price, Forfeited | $ / shares	$ 6.88
Weighted-Average Life (years), Forfeited
Outstanding, Expired | shares
Weighted-Average Exercise Price, Expired | $ / shares
Weighted-Average Life (years), Expired
Outstanding, Ending Balance | shares	2,679,058
Weighted-Average Exercise Price, Ending Balance | $ / shares	$ 6.97
Weighted-Average Life (years), Ending Balance	8 years 9 months 18 days
Outstanding, Ending Balance | shares	1,567,950
Weighted-Average Exercise Price, Ending Balance | $ / shares	$ 5.95
Weighted-Average Life (years), Ending Balance	8 years 4 months 24 days

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Related Party Transactions [Abstract]
Incurred interest expense	$ 16,664	$ 16,838
Incurred accretion expense	6,807	7,885
Recorded expenses	$ 52,264	$ 126,173

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Remuneration of Directors and Key Management Personnel - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Schedule of Remuneration of Directors and Key Management Personnel [Abstract]
Salaries and benefits	$ 921,492	$ 1,264,187

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Remuneration Paid to Related Parties - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Schedule of Remuneration Paid to Related Parties [Abstract]
Salaries and benefits	$ 14,956	$ 61,116

Government Grants (Details)

Government Grants (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Government Grants [Abstract]
Multi-marker test	$ 35,852
Antibody-based pathogens		$ 81,706

Government Grants (Details) - S

Government Grants (Details) - Schedule of Research and Development - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Schedule of Research and Development [Abstract]
Rapid detection of antibody-based pathogens		$ 19,072
Multi-marker test for the early detection of pancreatic cancer	28,117	50,037
Total research and development projects	$ 28,117	$ 69,109

Financial Instrument Risk Man_3

Financial Instrument Risk Management (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 USD ($)
Financial Instrument Risk Management [Abstract]
Federal insured limit	$ 250,000	€ 100,000
Bad debt expense	53,295		$ 0
Unrestricted cash	10,911,087
Current liabilities	$ 6,475,516
Foreign exchange risk, description	As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate its estimated short term operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which we also expect to be the currency of the Company’s largest cash outlays over the next twenty-four months.	As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate its estimated short term operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which we also expect to be the currency of the Company’s largest cash outlays over the next twenty-four months.

Financial Instrument Risk Man_4

Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities Financial Liabilities	Dec. 31, 2023 USD ($)
Within one year [Member]
Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities Financial Liabilities [Line Items]
Accounts payable and accrued liabilities	$ 4,326,662
Convertible promissory note to be settled with ordinary shares	5,015,000
Convertible loans	76,252
Silent partnerships	423,988
Lease liabilities	472,767
Payable for acquisition of intangible asset - related party	393,483
Total	10,708,152
More than one year [Member]
Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities Financial Liabilities [Line Items]
Accounts payable and accrued liabilities
Convertible promissory note to be settled with ordinary shares
Convertible loans
Silent partnerships	984,461
Lease liabilities	1,059,089
Payable for acquisition of intangible asset - related party	874,698
Total	2,918,248
More than five years [Member]
Financial Instrument Risk Management (Details) - Schedule of Contractual Maturities Financial Liabilities [Line Items]
Accounts payable and accrued liabilities
Convertible promissory note to be settled with ordinary shares
Convertible loans
Silent partnerships
Lease liabilities	501,319
Payable for acquisition of intangible asset - related party
Total	$ 501,319

Concentrations (Details)

Concentrations (Details)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Concentrations [Abstract]
Annual revenues percentage	10%
Number of customers	1	4
Revenue percentage	18%	81%

Operating Expenses (Details) -

Operating Expenses (Details) - Schedule of Operating Expenses - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Research and development [Member]
Operating Expenses (Details) - Schedule of Operating Expenses [Line Items]
Payroll expenses	$ 2,010,670	$ 539,204
Clinical study expenses	2,827,894	179,445
Depreciation and amortization	210,875
Travel expenses	100,383	13,138
Lab consumables	35,221	97
Other expenses	551,330	61,604
Research and development total	5,736,373	793,488
Sales and marketing [Member]
Operating Expenses (Details) - Schedule of Operating Expenses [Line Items]
Payroll expenses	707,833	370,597
Consulting services	1,143,077	123,333
Product and brand advertising	2,176,808	2,247,142
Other expenses	57,943	46,942
Sales and marketing total	4,085,661	2,788,014
General and administrative [Member]
Operating Expenses (Details) - Schedule of Operating Expenses [Line Items]
Payroll expenses	923,351	1,132,948
Stock option expense	1,668,673	4,894,450
Depreciation and amortization	246,710	62,369
Travel and car expenses	69,924	146,861
Consulting services	1,146,792	2,005,889
IT expense	107,101
Training	1,050	3,755
Insurance and taxes	478,149	529,120
Rent and Premises	77,672	83,732
Other expenses	159,929	266,083
General and administrative total	$ 4,879,351	$ 9,125,207

Subsequent Events (Details)

Subsequent Events (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) shares
Subsequent Events [Abstract]
Converted in principal value | $	$ 500,000
Ordinary shares net proceeds | shares	134,458